US-based pharmaceutical major Merck has opened a €100m R&D facility at Ballydine, Co Tipperary, Ireland.

The facility will house 70 new R&D roles, with the capacity to expand to 120 should new innovative medicines be developed. An additional investment of €6m is already planned to cater for the extra capacity.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Six drugs are currently in development at the facility, including Merck’s candidate drug for the treatment of hepatitis C and a dual high cholesterol/type II diabetes medication.

Three of Merck’s five top priority candidate medicine research programmes are now based at the facility.

Ballydine will also supply materials to support Merck’s worldwide clinical research programme.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now